See more : Tahera Diamond Corporation (TAHEF) Income Statement Analysis – Financial Results
Complete financial analysis of Oncolytics Biotech Inc. (ONCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncolytics Biotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fortune Valley Treasures, Inc. (FVTI) Income Statement Analysis – Financial Results
- G Mining Ventures Corp. (GMIN.TO) Income Statement Analysis – Financial Results
- SIGMAXYZ Holdings Inc. (6088.T) Income Statement Analysis – Financial Results
- Adbri Limited (ADBCF) Income Statement Analysis – Financial Results
- Flughafen Wien Aktiengesellschaft (FLU.VI) Income Statement Analysis – Financial Results
Oncolytics Biotech Inc. (ONCY)
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Cost of Revenue | 403.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 0.00 | 0.00 | 4.85M | 5.33M | 4.19M | 3.78M | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -403.00K | -392.00K | -452.07K | -446.19K | -485.57K | -95.38K | -90.77K | -162.23K | -180.41K | 0.00 | 0.00 | 0.00 | -5.33M | -4.19M | -3.78M | -4.31M | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 17.71M | 15.43M | 12.92M | 12.94M | 11.13M | 9.42M | 9.39M | 9.77M | 8.60M | 13.82M | 18.51M | 31.40M | 23.39M | 12.19M | 12.15M | 13.35M | 11.32M | 10.54M | 9.31M | 7.11M | 3.31M | 4.28M | 5.12M | 3.69M | 486.66K |
| General & Administrative | 16.08M | 11.49M | 13.32M | 12.51M | 0.00 | 0.00 | 0.00 | 5.36M | 5.14M | 0.00 | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -452.49K | -445.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.08M | 11.49M | 12.86M | 12.07M | 8.84M | 7.08M | 6.21M | 5.36M | 5.14M | 5.00M | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 4.53M | 4.03M | 3.15M | 5.47M | 2.95M | 2.10M | 1.56M | 1.06M | 89.03K |
| Other Expenses | 0.00 | 0.00 | 13.31M | 12.51M | 9.56M | 7.24M | 6.21M | 162.23K | 180.41K | 5.00M | 5.02M | 4.55M | 0.00 | 409.84K | 425.40K | 341.97K | 5.53M | 4.96M | 4.00M | 6.22M | 3.62M | 2.68M | 2.02M | 1.27M | 90.71K |
| Operating Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 15.51M | 17.00M | 13.76M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Cost & Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 19.70M | 17.00M | 18.07M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Interest Income | 1.33M | 528.00K | 98.61K | 121.19K | 179.28K | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | 416.25K | 76.93K | 30.83K | 519.26K | 1.21M | 1.23M | 783.46K | 699.76K | 313.31K | 208.87K | 655.21K | 905.69K | 0.00 |
| Interest Expense | 0.00 | 528.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 81.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 163.50K | 131.62K | 109.28K | 92.59K | 63.16K | 257.25K | 410.25K | 1.00M | 926.68K | 855.99K | 751.76K | 663.52K | 574.24K | 465.45K | 205.20K | 1.68K |
| EBITDA | -33.71M | -26.83M | -25.66M | -25.37M | -20.02M | -17.18M | -15.51M | -15.13M | -13.74M | -18.66M | -23.77M | -36.58M | -27.93M | -19.29M | -16.75M | -17.66M | -15.83M | -14.53M | -12.46M | -12.58M | -5.95M | -6.18M | -6.67M | -4.44M | -575.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -753.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,457.86% | -1,651.52% | -1,296.66% | -2,957.46% | 0.00% | -1,432.41% | -57,569,100.00% |
| Operating Income | -33.79M | -28.57M | -26.23M | -25.46M | -20.69M | -16.66M | -15.61M | -15.29M | -13.92M | -18.82M | -23.90M | -36.69M | -28.72M | -20.04M | -17.00M | -18.07M | -16.85M | -15.50M | -12.53M | -12.63M | -6.62M | -6.75M | -7.14M | -4.65M | -577.37K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -756.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,599.39% | -1,805.23% | -2,112.40% | -3,232.38% | 0.00% | -1,498.60% | -57,737,000.00% |
| Total Other Income/Expenses | 6.14M | 2.17M | -20.06K | 2.95M | -12.43M | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | -283.43K | 76.93K | 30.83K | 519.26K | 1.20M | 1.20M | 529.09K | -323.88K | -1.89M | 0.00 | 655.21K | 905.69K | 0.00 |
| Income Before Tax | -27.66M | -24.75M | -26.25M | -22.51M | -33.12M | -16.49M | -15.48M | -15.13M | -13.72M | -18.61M | -23.53M | -36.34M | -29.00M | -19.97M | -16.97M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.51M | -6.75M | -6.48M | -3.74M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.66% | -1,851.52% | -2,716.36% | -3,232.38% | 0.00% | -1,206.44% | 0.00% |
| Income Tax Expense | 97.00K | 84.00K | 49.43K | -2.95M | 12.43M | 548.04K | 141.50K | 9.37K | 3.15K | 6.78K | 5.41K | 30.47K | 40.00K | 7.61K | 23.04K | 0.00 | -1.20M | -1.20M | -1.53K | 323.88K | 33.55K | -659.90K | -310.57K | -126.81K | -2.91K |
| Net Income | -27.75M | -24.84M | -26.30M | -19.55M | -45.55M | -17.04M | -15.62M | -15.14M | -13.72M | -18.62M | -23.53M | -36.37M | -29.04M | -19.97M | -17.00M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.54M | -6.09M | -6.17M | -3.61M | -574.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.47% | -1,851.52% | -2,727.07% | -2,916.44% | 0.00% | -1,165.53% | -57,446,200.00% |
| EPS | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -2.09 | -0.93 |
| EPS Diluted | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -1.98 | -0.93 |
| Weighted Avg Shares Out | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.73M | 616.48K |
| Weighted Avg Shares Out (Dil) | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.83M | 616.48K |
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN...
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy...
ONCY Stock Up on Regulatory Update From Breast Cancer Program
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling...
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving...
Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the...
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat...
Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2024 Results Conference Call August 1, 2024 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communication Wayne Pisano - Chair of Oncolytics' Board of Directors, and Interim CEO Tom...
Source: https://incomestatements.info
Category: Stock Reports